Weight loss, in a once-daily tablet.
The proven GLP-1 science of Wegovy & Mounjaro — without the needle. Be first when it lands in the UK.
GLP-1 tablets vs injections
Two routes to the same active science. Tablets are coming soon; injections are available today — here's how they compare.
Figures are clinical trial averages — individual results vary. Weight-loss medicines are prescription-only and require a free consultation reviewed by a UK prescriber.
The two tablets coming to the UK
Both are once-daily oral GLP-1 medicines in late-stage development. Join the waitlist and we'll tell you the moment either is available.
Under MHRA review · closest
Phase 3 complete · next in lineTrial averages — individual results vary. Joining the waitlist does not guarantee supply or a prescription. Oral GLP-1 medicines are not yet licensed in the UK; availability is subject to MHRA approval.
Next to land: the oral tablet.
Where every GLP-1 medicine we track sits with UK regulators — and which one reaches your door first.
The first oral GLP-1 tablet — the same active family as Wegovy, now with UK regulators.
A small-molecule oral GLP-1 — no special storage. Phase 3 complete, UK filing expected during 2026.
Notify me when it landsfrom £89 / month · weekly injection
Explore injections available nowGet first access to oral GLP-1 treatment
Waitlist members get the earliest route to tablets — and the best terms when they launch.
One daily pill.
No needles,
no fridge.
The oral GLP-1 tablet, coming to the UK soon.
Priority access to consultations
Waitlist members book the first consultation slots the day treatment goes live — ahead of everyone else.
Exclusive launch pricing
An early-access price held for members only — kept lower than the open-market rate at launch.
One honest email — no spam
We write once: the day oral GLP-1 is genuinely dispensable in the UK. No countdowns, no marketing drip.
Don't want to wait?
These weight-loss treatments are in stock now — started online after a free consultation with a UK prescriber.
Clinical trial averages — individual results vary. Prescription-only medicines; suitability is assessed in a free online consultation reviewed by a UK prescriber. Discount codes are subject to terms.
The honest unknowns
We're a pharmacy, not a fortune-teller. Here's what we genuinely don't know yet — and we'll update the moment we do.
Manufacturers haven't set UK prices for oral GLP-1. We'll publish ours — and honour waitlist launch pricing — as soon as supply terms are confirmed.
Oral semaglutide is under MHRA review with an estimated H2 2026 window, but regulators set the date — not us. Anyone promising a firm day right now is guessing.
Whether oral GLP-1 is offered on the NHS, and to whom, will be decided separately by NICE and local services. We'll signpost the criteria when they're published.
Trial averages suggest injections currently edge ahead on weight loss, but head-to-head, real-world data is still maturing. We won't overstate the tablet.
A real UK pharmacy, on the record
GPhC-registered pharmacy
EveryDayMeds is operated by OVIO Ltd and registered with the General Pharmaceutical Council: 9012878.
Check the GPhC registerOral GLP-1 is not yet licensed in the UK. Joining the waitlist does not create a prescription or guarantee supply. All treatment decisions are made by a prescriber based on your individual suitability.
Oral GLP-1, answered honestly
It's an oral form of the same GLP-1 medicine class used in injections like Wegovy and Mounjaro. Instead of a weekly injection, you take a once-daily tablet that works on the same appetite-regulating pathways.
Oral semaglutide is under MHRA review with an estimated H2 2026 window. Regulators set the final date, not us — so we won't promise a firm day. Join the waitlist and we'll email you the moment it's genuinely dispensable.
Current trial averages suggest injections still edge ahead slightly on weight loss, but the tablet removes needles, fridge storage and sharps disposal. Head-to-head real-world data is still maturing.
No. Joining is free and creates no prescription, payment or obligation. It simply means you're first to know — and first in line for any launch pricing — when it lands.
Eligibility will follow the same clinical criteria as our injectable treatments and is assessed in a free online consultation reviewed by a UK-registered prescriber. Suitability is decided case by case.
GLP-1 medicines most commonly cause mild, temporary digestive effects such as nausea, reduced appetite or changes in bowel habits, usually easing as your body adjusts. Your prescriber will review the full safety information with you.
Yes. GLP-1 treatments are prescription-only medicines. You'll complete a short online consultation that a UK-registered prescriber reviews before any treatment is approved.
Potentially, once the tablet is licensed — but any switch must be reviewed and agreed by a prescriber, who will consider your current dose, response and medical history before making a recommendation.
As with our current treatments, approved orders are dispensed by our GPhC-registered pharmacy and sent in discreet, tracked packaging — typically dispatched within 24 hours of approval.
Yes. EveryDayMeds is operated by OVIO Ltd and registered with the General Pharmaceutical Council (GPhC 9012878). We dispense only genuine, MHRA-licensed medicines against a valid prescription.